Form 4: Aligos Therapeutics Officer Acquires 72,000 Stock Options

Matthew W. McClure, Chief Medical Officer of Aligos Therapeutics, acquired 72,000 stock options on March 1, 2024.

Summary

• Matthew W. McClure, the Chief Medical Officer of Aligos Therapeutics, Inc. (ALGS), filed a Form 4 on March 4, 2024, reporting a transaction.
• On March 1, 2024, McClure acquired 72,000 stock options with an exercise price of $1.13.
• These options vest in 48 equal monthly installments starting March 1, 2024, and will be fully vested on the fourth anniversary of this date, contingent upon continued service.
• Following the transaction, McClure directly owns 72,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of stock options could be seen as a positive sign, but it's not definitive.

Positives

• The acquisition of stock options by a high-ranking officer may indicate confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the Chief Medical Officer.

Key Dates